An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of synthetic anti-infectives.
View the full Corporate Spotlight
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 49.0¢ | Day High | 49.0¢ | Day Low | 44.0¢ | |||
| Daily Volume | 265969 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 2 | 44.0¢ | 8037 | 2 | 44.5¢ | 7247 | |
| Mr. James Hamilton Bray Graham | Chief Executive Officer, Managing Director, Executive Director |
| Mr. Justin Reynolds | Chief Financial Officer |
| Ms. Michele Keryn Dilizia | Chief Scientific Officer, Executive Director |
| Dr. Philip Sutton | Vice President of Translational Sciences |
| Dr. Justin Ward | Executive Director and Principal Quality Chemist |
| Mr. Daniel Astudillo | Head of Marketing |
| Mr. Thomas Jarrett | Operations Manager |
| Ms. Maggie Niewidok | Company Secretary |
| Dr. John Prendergast | Independent Non- Executive Chairman of the Board |
| Mr. Alistair McKeough | Non-Executive Director |
| Dr. Alan William Dunton | Non-Executive Independent Director |
Data source: Refinitiv
 (20min delay)
|
|||||
|
Last
44.0¢ |
Change
-0.040(8.33%) |
Mkt cap ! $127.2M | |||
| Open | High | Low | Value | Volume |
| 49.0¢ | 49.0¢ | 44.0¢ | $122.7K | 265.9K |
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 8037 | 44.0¢ |
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 7247 | 2 |
| Last trade - 16.10pm 10/09/2025 (20 minute delay) ? |
|
|||||
|
Last
44.0¢ |
Change
-0.040 ( 9.13 %) |
||||
| Open | High | Low | Volume | ||
| 49.0¢ | 49.0¢ | 44.0¢ | 82313 | ||
| Last updated 15.14pm 10/09/2025 ? | |||||
| RCE (ASX) Chart |
